^
BIOMARKER:

MET overexpression

i
Other names: DFNB97, AUTS9, RCCP2, C-Met, HGFR, HGF Receptor, Met Proto-Oncogene, HGF/SF Receptor, Proto-Oncogene C-Met, Scatter Factor Receptor, Tyrosine-Protein Kinase Met, Hepatocyte Growth Factor Receptor, MET, MET Proto-Oncogene, Receptor Tyrosine Kinase
Entrez ID:
MET overexpression
NSCLC
SCC244
Sensitive: C2 – Inclusion Criteria
MET overexpression
Lung Non-Squamous Non-Small Cell Cancer
ABBV-399
Sensitive: C2 – Inclusion Criteria
MET overexpression
NSCLC
erlotinib + ARQ 197
Sensitive: C3 – Early Trials
MET overexpression
Gastric Cancer
ARQ 197
Sensitive: C3 – Early Trials
MET overexpression
Melanoma
vemurafenib
Resistant: C3 – Early Trials
MET overexpression
CRC
EGFR inhibitor
Resistant: C3 – Early Trials
MET overexpression
GBM
bevacizumab
Resistant: C3 – Early Trials
MET overexpression
HCC
tepotinib
Sensitive: C3 – Early Trials
MET overexpression
Gastric Cancer
crizotinib
Sensitive: C3 – Early Trials
MET overexpression
Gastric Cancer
savolitinib
Sensitive: C3 – Early Trials
MET overexpression
Pancreatic Cancer
cetuximab
Resistant: C4 – Case Studies
MET overexpression
Pancreatic Cancer
trametinib + dabrafenib
Resistant: C4 – Case Studies
MET overexpression
Pancreatic Cancer
TR1801-ADC
Sensitive: D – Preclinical
MET overexpression
Adrenal Cortex Carcinoma
cabozantinib capsule
Sensitive: D – Preclinical
MET overexpression
LUAD
CKD-702
Sensitive: D – Preclinical
MET overexpression
Melanoma
BRAF inhibitor + MEK inhibitor
Resistant: D – Preclinical
MET overexpression
HCC
WXSH0011
Sensitive: D – Preclinical
MET overexpression
Gastric Cancer
tepotinib
Sensitive: D – Preclinical
MET overexpression
NSCLC
crizotinib + chidamide
Sensitive: D – Preclinical
MET overexpression
NSCLC
MG132
Sensitive: D – Preclinical
MET overexpression
Gastric Cancer
WXSH0011
Sensitive: D – Preclinical
MET overexpression
Gastric Cancer
Sym015
Sensitive: D – Preclinical